These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 32537926)

  • 1. Case of post-progression prolongation of survival after cessation of pembrolizumab in advanced non-small-cell lung cancer.
    Liu J; Wong K; Patanjali N; Boyer M; Kao S
    Intern Med J; 2020 Jun; 50(6):771-773. PubMed ID: 32537926
    [No Abstract]   [Full Text] [Related]  

  • 2. Advanced non-small cell lung cancer - treatment with Pembrolizumab.
    Silvinato A; Floriano I; Bernardo WM
    Rev Assoc Med Bras (1992); 2020 Mar; 66(3):256. PubMed ID: 32520141
    [No Abstract]   [Full Text] [Related]  

  • 3. Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer.
    Gandhi L; Rodríguez-Abreu D; Gadgeel S; Esteban E; Felip E; De Angelis F; Domine M; Clingan P; Hochmair MJ; Powell SF; Cheng SY; Bischoff HG; Peled N; Grossi F; Jennens RR; Reck M; Hui R; Garon EB; Boyer M; Rubio-Viqueira B; Novello S; Kurata T; Gray JE; Vida J; Wei Z; Yang J; Raftopoulos H; Pietanza MC; Garassino MC;
    N Engl J Med; 2018 May; 378(22):2078-2092. PubMed ID: 29658856
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real-World Experience With Pembrolizumab in Patients With Advanced Lung Cancer.
    Peng TR; Wu TW
    Am J Ther; 2019; 26(4):e537-e538. PubMed ID: 30946046
    [No Abstract]   [Full Text] [Related]  

  • 5. Pembrolizumab provides long-term survival benefits in advanced non-small cell lung cancer: The 5-year outcomes of the KEYNOTE-024 trial.
    Li F; Dong X
    Thorac Cancer; 2021 Dec; 12(23):3085-3087. PubMed ID: 34643064
    [No Abstract]   [Full Text] [Related]  

  • 6. First-line treatment for patients with advanced non-small cell lung carcinoma and high PD-L1 expression: pembrolizumab or pembrolizumab plus chemotherapy.
    Zhou Y; Lin Z; Zhang X; Chen C; Zhao H; Hong S; Zhang L
    J Immunother Cancer; 2019 May; 7(1):120. PubMed ID: 31053172
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater.
    Reck M; Rodríguez-Abreu D; Robinson AG; Hui R; Csőszi T; Fülöp A; Gottfried M; Peled N; Tafreshi A; Cuffe S; O'Brien M; Rao S; Hotta K; Vandormael K; Riccio A; Yang J; Pietanza MC; Brahmer JR
    J Clin Oncol; 2019 Mar; 37(7):537-546. PubMed ID: 30620668
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bullous pemphigoid induced by pembrolizumab in a patient with non-small-cell lung cancer who achieved durable complete response despite treatment cessation and long-term corticosteroid administration: A case report.
    Muto Y; Namikawa K; Fujiwara Y; Mori T; Nakano E; Takahashi A; Yamazaki N
    J Dermatol; 2020 Jan; 47(1):e9-e11. PubMed ID: 31674068
    [No Abstract]   [Full Text] [Related]  

  • 9. Ramucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer, gastro-oesophageal cancer, or urothelial carcinomas (JVDF): a multicohort, non-randomised, open-label, phase 1a/b trial.
    Herbst RS; Arkenau HT; Santana-Davila R; Calvo E; Paz-Ares L; Cassier PA; Bendell J; Penel N; Krebs MG; Martin-Liberal J; Isambert N; Soriano A; Wermke M; Cultrera J; Gao L; Widau RC; Mi G; Jin J; Ferry D; Fuchs CS; Petrylak DP; Chau I
    Lancet Oncol; 2019 Aug; 20(8):1109-1123. PubMed ID: 31301962
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Complete Pathologic Response When Adding Pembrolizumab to Neoadjuvant Chemotherapy in Stage IIIA Non-Small-Cell Lung Cancer.
    Hill A; Gong J; Wilczynski S; Mirza R; Erhunmwunsee L; Salgia R
    J Oncol Pract; 2018 Sep; 14(9):569-571. PubMed ID: 30044685
    [No Abstract]   [Full Text] [Related]  

  • 11. Cytokine Release Syndrome with Pseudoprogression in a Patient with Advanced Non-Small Cell Lung Cancer Treated with Pembrolizumab.
    Kogure Y; Ishii Y; Oki M
    J Thorac Oncol; 2019 Mar; 14(3):e55-e57. PubMed ID: 30782385
    [No Abstract]   [Full Text] [Related]  

  • 12. Fatal encephalopathy after pembrolizumab treatment for advanced non-small cell lung carcinoma.
    Freitas C; Sampaio L; Fernandes G
    J Neurooncol; 2019 Nov; 145(2):399-402. PubMed ID: 31506753
    [No Abstract]   [Full Text] [Related]  

  • 13. Cost-effectiveness of pembrolizumab for advanced non-small cell lung cancer patients with varying comorbidity burden.
    Criss SD; Palazzo L; Watson TR; Paquette AM; Sigel K; Wisnivesky J; Kong CY
    PLoS One; 2020; 15(1):e0228288. PubMed ID: 31995619
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Advanced non-small cell lung cancer - Treatment with Pembrolizumab.
    Silvinato A; Floriano I; Bernardo WM
    Rev Assoc Med Bras (1992); 2019 Dec; 65(12):1423-1432. PubMed ID: 31994619
    [No Abstract]   [Full Text] [Related]  

  • 15. Q-TWiST Analysis to Assess Benefit-Risk of Pembrolizumab in Patients with PD-L1-Positive Advanced or Metastatic Non-small Cell Lung Cancer.
    Huang M; Pietanza MC; Samkari A; Pellissier J; Burke T; Chandwani S; Kong F; Pickard AS
    Pharmacoeconomics; 2019 Jan; 37(1):105-116. PubMed ID: 30515719
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Histologic Transformation in a Patient with Lung Cancer Treated with Chemotherapy and Pembrolizumab.
    Hsu CL; Chen KY; Kuo SW; Chang YL
    J Thorac Oncol; 2017 Jun; 12(6):e75-e76. PubMed ID: 28532567
    [No Abstract]   [Full Text] [Related]  

  • 17. Cost-effectiveness analysis of pembrolizumab monotherapy and chemotherapy in the non-small-cell lung cancer with different PD-L1 tumor proportion scores.
    Zhou K; Jiang C; Li Q
    Lung Cancer; 2019 Oct; 136():98-101. PubMed ID: 31476529
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and efficacy of pembrolizumab monotherapy in elderly patients with PD-L1-positive advanced non-small-cell lung cancer: Pooled analysis from the KEYNOTE-010, KEYNOTE-024, and KEYNOTE-042 studies.
    Nosaki K; Saka H; Hosomi Y; Baas P; de Castro G; Reck M; Wu YL; Brahmer JR; Felip E; Sawada T; Noguchi K; Han SR; Piperdi B; Kush DA; Lopes G
    Lung Cancer; 2019 Sep; 135():188-195. PubMed ID: 31446994
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An unknown reaction to pembrolizumab: giant cell arteritis.
    Micaily I; Chernoff M
    Ann Oncol; 2017 Oct; 28(10):2621-2622. PubMed ID: 28633343
    [No Abstract]   [Full Text] [Related]  

  • 20. Autoimmune-Related Primary Hypoparathyroidism Possibly Induced by the Administration of Pembrolizumab: A Case Report.
    Umeguchi H; Takenoshita H; Inoue H; Kurihara Y; Sakaguchi C; Yano S; Hasuzawa N; Sakamoto S; Sakamoto R; Ashida K
    J Oncol Pract; 2018 Jul; 14(7):449-451. PubMed ID: 29906213
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.